Head to Head Survey: Adverum Biotechnologies (NASDAQ:ADVM) and Scinai Immunotherapeutics (NASDAQ:SCNI)

Scinai Immunotherapeutics (NASDAQ:SCNI) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings for Scinai Immunotherapeutics and Adverum Biotechnologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	0	0	0	0	0.00
Adverum Biotechnologies	0	1	5	0	2.83

Adverum Biotechnologies has a consensus target price of $27.83, suggesting a potential upside of 370.95%. Given Adverum Biotechnologies’ stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than Scinai Immunotherapeutics.

Earnings and Valuation

This table compares Scinai Immunotherapeutics and Adverum Biotechnologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	N/A	N/A	-$6.50 million	($239.17)	-0.01
Adverum Biotechnologies	$3.60 million	34.15	-$117.17 million	($5.99)	-0.99

Scinai Immunotherapeutics has higher earnings, but lower revenue than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Scinai Immunotherapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Profitability

This table compares Scinai Immunotherapeutics and Adverum Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	-30.48%
Adverum Biotechnologies	N/A	-65.14%	-40.52%

Summary

Scinai Immunotherapeutics beats Adverum Biotechnologies on 7 of the 12 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.